Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis

The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.

two roads — Immunic is exploring several paths forward for vidofludimus calcium • Source: Shutterstock

Immunic Inc announced positive Phase II data for vidofludimus calcium in ulcerative colitis, contributing to management’s decision to invest more in that asset and pivot away from a different drug candidate, izumerogant (IMU-935), an oral drug n development for psoriasis.

Vidofludimus calcium is Immunic’s lead drug candidate, but the development focus has been on multiple sclerosis (MS), where the company is studying it in a Phase III study in relapsing-remitting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.